Sells prescription medicines and develops injectable drug candidates for people with endocrine and neurological diseases.
10-K for FY2025, filed Mar 2, 2026
Sells its products mainly to wholesalers or a specialty pharmacy, with product sales counted when those buyers obtain the goods; collaboration and technology-partnership revenue is earned under contract terms.
10-K for FY2025, filed Mar 2, 2026The Company sells product primarily to wholesalers or a specialty pharmacy that subsequently resell to retail pharmacies or patients. The…View ↗
Revenue is recognized when the Company's customer (e.g., a wholesaler or specialty pharmacy) obtains control of promised goods, which is…View ↗
Royalty and contract revenue is recognized as earned in accordance with contract terms when it can be reasonably estimated and…View ↗
10-K for FY2025, filed Mar 2, 2026
FY2025 revenue by product or service ↗$291.8M
10-K for FY2025, filed Mar 2, 2026
$291.8M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenue, net
Sold outright
10-K for FY2025, filed Mar 2, 2026 |
97%
FY2022: 99%
|
Product revenue, net, FY2025
$283M Sources
|
Sold outright |
|
Royalty, contract and other revenue
|
3.0%
FY2022: 0.9%
|
Royalty, contract and other revenue, FY2025
$8.8M Sources
|
Xeris sells mainly to wholesalers or a specialty pharmacy, which resell products to retail pharmacies or patients; it also works with payors, group purchasing organizations and healthcare providers on rebates and discounts.
Yes. It kept less than a cent of every revenue dollar as net income in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
$11.3MView ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
8-K, filed Aug 6, 2026
Tightens full-year 2026 total revenue guidance to $385 million to $390 millionView ↗
8-K, filed Jun 30, 2026
On June 29, 2026, the Board appointed John Shannon, the Company’s Chief Executive Officer, to serve as Chairperson of the Board, effective…View ↗
Growing. Revenue grew 5.9x in 4 years, from $49.6M in FY2021 to $291.8M in FY2025, about 56% a year.
Pipeline development
The older report described the levothyroxine candidate as an early-stage program with a dose-finding study planned; the latest report says the dose-finding study is complete and a pivotal trial is planned.
10-K for FY2022, filed Mar 8, 2023 10-K for FY2025, filed Mar 2, 2026We conducted a Phase 1 clinical study with product candidate XP-8121, an early-stage program designed to address maintenance therapy in…View ↗
Competes with Corcept Therapeutics, Teva Pharmaceutical Industries, Recordati Rare Diseases, HRA Pharma, Sparrow Pharmaceuticals, Crinetics Pharmaceuticals, Stero Therapeutics, Lundbeck, Amphastar, Zealand Pharma, Fresenius Kabi, Torrent Pharmaceuticals, Cycle Pharmaceuticals, and Rising Pharmaceuticals
10-K for FY2025, filed Mar 2, 2026Recorlev: A number of therapies are currently approved or in various stages of development for endogenous Cushing’s syndrome. Korlym…View ↗
Loading...